JP5669741B2 - 培養システム - Google Patents
培養システム Download PDFInfo
- Publication number
- JP5669741B2 JP5669741B2 JP2011533349A JP2011533349A JP5669741B2 JP 5669741 B2 JP5669741 B2 JP 5669741B2 JP 2011533349 A JP2011533349 A JP 2011533349A JP 2011533349 A JP2011533349 A JP 2011533349A JP 5669741 B2 JP5669741 B2 JP 5669741B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- dimensional
- insert
- poly
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000642 polymer Polymers 0.000 claims description 73
- 229920001577 copolymer Polymers 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 36
- 229920002678 cellulose Polymers 0.000 claims description 25
- 108010035532 Collagen Proteins 0.000 claims description 24
- 102000008186 Collagen Human genes 0.000 claims description 24
- 229920001436 collagen Polymers 0.000 claims description 24
- 239000012530 fluid Substances 0.000 claims description 21
- 108010010803 Gelatin Proteins 0.000 claims description 19
- 229920000954 Polyglycolide Polymers 0.000 claims description 19
- 238000004113 cell culture Methods 0.000 claims description 19
- 239000008273 gelatin Substances 0.000 claims description 19
- 229920000159 gelatin Polymers 0.000 claims description 19
- 235000019322 gelatine Nutrition 0.000 claims description 19
- 235000011852 gelatine desserts Nutrition 0.000 claims description 19
- 239000004633 polyglycolic acid Substances 0.000 claims description 18
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 16
- 229920001707 polybutylene terephthalate Polymers 0.000 claims description 14
- 229920001610 polycaprolactone Polymers 0.000 claims description 14
- 239000004632 polycaprolactone Substances 0.000 claims description 14
- 229920000615 alginic acid Polymers 0.000 claims description 13
- 239000000783 alginic acid Substances 0.000 claims description 13
- 235000010443 alginic acid Nutrition 0.000 claims description 13
- 229960001126 alginic acid Drugs 0.000 claims description 13
- 150000004781 alginic acids Chemical class 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 13
- 239000004626 polylactic acid Substances 0.000 claims description 13
- 239000004005 microsphere Substances 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 11
- 239000000017 hydrogel Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Chemical class 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 8
- -1 sheet Substances 0.000 claims description 8
- 229920000936 Agarose Polymers 0.000 claims description 7
- 102000009123 Fibrin Human genes 0.000 claims description 7
- 108010073385 Fibrin Proteins 0.000 claims description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 150000008064 anhydrides Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 229950003499 fibrin Drugs 0.000 claims description 7
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 7
- 229920000728 polyester Polymers 0.000 claims description 7
- 229920002451 polyvinyl alcohol Chemical class 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 229920000742 Cotton Polymers 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- 229920001605 Dextranomer Polymers 0.000 claims description 6
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Chemical class 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 108010085895 Laminin Proteins 0.000 claims description 6
- 102000007547 Laminin Human genes 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 102100037369 Nidogen-1 Human genes 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229960002864 dextranomer Drugs 0.000 claims description 6
- 229920002549 elastin Chemical class 0.000 claims description 6
- 239000004744 fabric Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 108010082117 matrigel Proteins 0.000 claims description 6
- 108010008217 nidogen Proteins 0.000 claims description 6
- 229920001983 poloxamer Chemical class 0.000 claims description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 6
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 6
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 6
- 229920001299 polypropylene fumarate Polymers 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000002729 catgut Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 194
- 239000011159 matrix material Substances 0.000 description 94
- 210000001519 tissue Anatomy 0.000 description 91
- 210000004379 membrane Anatomy 0.000 description 76
- 239000012528 membrane Substances 0.000 description 76
- 210000002536 stromal cell Anatomy 0.000 description 45
- 230000012010 growth Effects 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 210000002950 fibroblast Anatomy 0.000 description 26
- 229920000747 poly(lactic acid) Polymers 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000012620 biological material Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000002356 single layer Substances 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000003630 growth substance Substances 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 229920003232 aliphatic polyester Polymers 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229960005188 collagen Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000012737 fresh medium Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000004738 parenchymal cell Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N L-valinic acid Natural products CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000011748 cell maturation Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 210000003668 pericyte Anatomy 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GHPVDCPCKSNJDR-UHFFFAOYSA-N 2-hydroxydecanoic acid Chemical compound CCCCCCCCC(O)C(O)=O GHPVDCPCKSNJDR-UHFFFAOYSA-N 0.000 description 2
- JYZJYKOZGGEXSX-UHFFFAOYSA-N 2-hydroxymyristic acid Chemical compound CCCCCCCCCCCCC(O)C(O)=O JYZJYKOZGGEXSX-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 210000004176 reticulum cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RILPIWOPNGRASR-RFZPGFLSSA-N (2R,3R)-2-hydroxy-3-methylpentanoic acid Chemical compound CC[C@@H](C)[C@@H](O)C(O)=O RILPIWOPNGRASR-RFZPGFLSSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- TYBSGNFITSHAJH-UHFFFAOYSA-N 2-ethyl-3-hydroxybutyric acid Chemical compound CCC(C(C)O)C(O)=O TYBSGNFITSHAJH-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- GZYXPXGNODDCBD-UHFFFAOYSA-N 3,3,6,6-tetramethyl-1,4-dioxane-2,5-dione Chemical compound CC1(C)OC(=O)C(C)(C)OC1=O GZYXPXGNODDCBD-UHFFFAOYSA-N 0.000 description 1
- ULKFLOVGORAZDI-UHFFFAOYSA-N 3,3-dimethyloxetan-2-one Chemical compound CC1(C)COC1=O ULKFLOVGORAZDI-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- GSCLMSFRWBPUSK-UHFFFAOYSA-N beta-Butyrolactone Chemical compound CC1CC(=O)O1 GSCLMSFRWBPUSK-UHFFFAOYSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229920006030 multiblock copolymer Polymers 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000004788 neurological cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229920006126 semicrystalline polymer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/30—Constructional details, e.g. recesses, hinges biodegradable
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
- C12M25/04—Membranes; Filters in combination with well or multiwell plates, i.e. culture inserts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Clinical Laboratory Science (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Materials For Medical Uses (AREA)
Description
本出願は、2008年10月22日出願の米国仮特許出願第61/107,640号の利益を主張し、その出願の全体は、参照により本明細書に組み込まれる。
本明細書において、三次元の細胞培養物または組織培養物を生育せしめるためのデバイスを提供し、このデバイスは、少なくとも1つの容器(マイクロプレートウエル)によって受容されて容器(マイクロプレートウエル)内部に少なくとも部分的に収容されるように構成されている少なくとも1つの挿入部を備え、各挿入部が、分解性、透過性の底壁と、個別の流体コンパートメントを画定する、底壁に接続された少なくとも1つの側壁とを含み、前記底壁のそれぞれが、各挿入部と容器(マイクロプレートウエル)の下位部との間の流体連通が可能になるように構成されている多孔性マトリックスを含み、前記少なくとも1つの挿入部のそれぞれが、前記底壁の上部に足場をさらに備える。
本明細書において言及する刊行物、特許および特許出願は全て、個々の刊行物、特許および特許出願がそれぞれ、参照により組み込まれることが具体的かつ個々に示されるのと同じ程度に、参照により本明細書に組み込まれる。
組織培養の器具(例えば、挿入部ウエル)においては、細胞試料または組織試料が、栄養培地から、透過性メンブランによって分離される。そこでは、栄養素の濃度勾配が発生し、この透過性メンブランを通して細胞を養うことができる。この配置は、in vivoにおける状況をより厳密に反映する。この透過性メンブランは、管状の支持体の底部末端につながり、一方、この支持体はその上端において、栄養素を含有するウエルの上部から、フランジによって垂れ下がる。支持体のフランジによって、支持体およびメンブランは、ウエルの中心に位置する。支持体の側壁中の開口部が、ウエルに流体を添加し、そこから流体を取り出すためのピペットの接近手段を提供する。
三次元の間質性支持体、培養システム自体、およびその維持、ならびに三次元培養物の種々の用途は、それらのそれぞれの全体が本明細書に組み込まれる米国特許第4,963,489号および第5,624,840号に、より詳細に記載されている。
(a)三次元マトリックスは、タンパク質の付着のため、およびその結果として、間質細胞の接着のためのより大きな表面積をもたらす。
(b)マトリックスが三次元であるため、間質細胞はコンフルエンスに到達するまで単層における細胞よりも長期にわたり活発に生育する。この長期間のサブコンフルエントな状態の間に複製する間質細胞によって産生される増殖因子および調節因子は、培養物中の増殖の刺激および細胞分化の調節に部分的に関与することができる。
(c)三次元マトリックスにより、in vivoにおいて対応する組織中に見出されるものにより類似する細胞要素の空間分布が可能になる。
(d)三次元のシステム中では、細胞を生育せしめるための潜在的な体積が増加することによって、細胞の成熟の助けとなる微小環境の局在化を確立することが可能になり得る。
(e)三次元マトリックスによって、付着層中のマクロファージ、単核球、およびおそらくリンパ球等の遊走細胞の動きについての可能性がより大きくなることにより、細胞間相互作用が最大となる。
本明細書で用いる場合、三次元マトリックス(足場)は、(a)細胞が、それに付着するのを可能にし(もしくは細胞がそれに付着するのが可能になるように改変することができ)、その中に組み込まれることを可能にし、またはその上部上に置かれる(付着しない)ことを可能にし、かつ(b)細胞が、二層以上に生育するのを可能にする任意の材料および/または形状から構成される。この支持体に間質細胞を接種して、三次元の間質性マトリックスを形成することができる。
線維芽細胞を含む間質細胞を、以下に記載するその他の細胞および要素を有しても有さなくても、該マトリックス上に接種してよい。これらの線維芽細胞は、臓器、例として、皮膚、肝臓、膵臓等から得てよい。それらの臓器は、(適切な場合には)生検によってか、または剖検時に得ることができる。実際に、任意の適切な死体臓器から、線維芽細胞を多量にかなり好都合に得ることができる。先に説明したように、胎性線維芽細胞を、多様な異なる細胞および/または組織の生育をサポートする「一般的な」三次元の間質性マトリックスを形成するために用いることができる。しかし、培養しようとする組織の同じ型から得た線維芽細胞、ならびに/または本発明の三次元のシステムによる培養物中で生育される細胞および/もしくは組織を後に受容しようとする特定の個体から得た線維芽細胞を、この三次元マトリックスに接種することによって、「特定の」間質性マトリックスを調製することができる。
本発明は一側面では、分解性、多孔性のメンブランを有する挿入ウエルデバイスである。挿入ウエルデバイスはマルチウエル挿入プレートとしても知られ、これら2つのデバイスを本明細書では互換的に指す。細胞の生育をサポートするために用いられるデバイスの部分は典型的にはメンブランであるところ、生育培地を含有するウエル内部にメンブランをぶら下げるために用いられるデバイスの部分に着脱可能に固定される。この配置によって、培養した細胞の操作が容易になる。
本発明の三次元の肝臓培養システムを、多様な適用例において用いることができる。これらが包含するのは、限定されないが、培養細胞のin vivoにおける移植または埋込み;in vitroにおける細胞傷害性化合物、発癌物質、変異原、増殖因子/調節因子、薬学的化合物等のスクリーニング;特定の疾患の機構の解明;薬物および/または増殖因子が作動する機構の研究;患者の癌の診断およびモニタリング;遺伝子治療;ならびに生物学的活性産物の産生が挙げられる。
Claims (17)
- 三次元の細胞培養物または組織培養物を生育せしめるためのデバイスであって、少なくとも1つの容器によって受容されて該容器内部に少なくとも部分的に収容されるように構成されている少なくとも1つの挿入部を備え、前記各挿入部は分解性、透過性の底壁と、個別の流体コンパートメントを画定する前記底壁に接続された少なくとも1つの側壁を含み、前記底壁のそれぞれは前記各挿入部と容器の下位部との間の流体連通が可能になるように構成されている、デバイス。
- 挿入部が流体を保持することができ、前記流体は各挿入部と容器の下位部との間で連通している、請求項1に記載のデバイス。
- 分解性、透過性の底壁が細胞性メッシュ、デキストラノマーマイクロスフェア、コラーゲン、ラミニン、エンタクチン、Matrigel、綿、セルロース、顆粒、シート、布、生分解性マイクロスフェア、ヒドロゲル、ガーゼ、改変多(糖類)、キトサン、デンプン、ゼラチンコポリマー製フィルム、生体適合性充填剤、アルギン酸、フィブリン、アガロース、改変アルギン酸、エラスチン、ゼラチン、ポリ(ビニルアルコール)、ポリ(エチレングリコール)、プルロニック、ポリ(ビニルピロリドン)、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロース、ポリ(エチレンテレフタレート)、ポリ(無水物)、ポリ(プロピレンフマレート)、ネコガット縫合糸、ゼラチン、デキストラン、混合セルロースエステル、ポリエステルで覆われた混合セルロースエステル、カルボン酸基強化ポリマー、ポリ(エチレンオキシド)(PEO)とポリ(ブチレンテレフタレート)(PBT)とのマルチブロックコポリマー、PHB−PHVクラスのポリ(ヒドロキシアルカノエート)、ポリ(エステル)、ポリ乳酸(PLA)のポリマーもしくはそのコポリマー、ポリグリコール酸(PGA)のポリマーもしくはそのコポリマー、ポリ乳酸−コ−グリコール酸(PLG)のコポリマーもしくはそのコポリマー、ポリカプロラクトン(PCL)もしくはそのコポリマー、および/またはそれらの混合物からなる群から選択される、請求項1に記載のデバイス。
- 挿入部がデバイスから取外し可能である、請求項1に記載のデバイス。
- 取外し可能な挿入部が接続されていない挿入部または複数の接続されている挿入部の部分である、請求項4に記載のデバイス。
- 少なくとも1つの挿入部がデバイスに溶接されている、請求項1に記載のデバイス。
- 底壁が10分〜1年の時間をかけて分解する、請求項1に記載のデバイス。
- 底壁が48時間超〜1年の時間をかけて分解する、請求項1に記載のデバイス。
- 挿入部中で培養された細胞が懸濁液中において生育し、底壁に付着し、外底壁に組み込まれ、および/または該底壁に三次元の足場を形成する、請求項1に記載のデバイス。
- 容器がマルチウエル容器である、請求項1に記載のデバイス。
- 少なくとも1つの挿入部のそれぞれが、底壁の上部に足場をさらに備える、請求項1に記載のデバイス。
- 足場が分解性であるかまたは非分解性である、請求項11に記載のデバイス。
- 挿入部中で培養された細胞が、足場に付着しない、付着する、足場内に組み込まれる、および/または三次元の培養物を形成する、請求項11に記載のデバイス。
- 細胞が足場に付着しない後に、付着した後に、足場内に組み込まれた後に、底壁が分解する、および/または三次元の培養物を形成する、請求項11に記載のデバイス。
- 以下を含むマルチウエルプレート容器:
第1のアレイを形成する複数の第1の容器、
第1のウエルの前記第1のアレイと整列され、第2のアレイを形成する複数の第2の容器、ここで
前記第1のアレイの容器と前記第2のアレイの容器は一緒に連結され、前記複数の第2の容器のそれぞれは請求項11に記載のデバイスを有する。 - 請求書1〜14のいずれかに記載のデバイスの、二次元の配置中または三次元の配置中の細胞培養物における使用。
- 三次元の細胞培養物または組織培養物を生育せしめるためのデバイスであって、少なくとも1つの容器によって受容されて該容器内部に少なくとも部分的に収容されるように構成されている少なくとも1つの挿入部を備え、前記各挿入部は分解性、透過性の底壁と、個別の流体コンパートメントを画定する前記底壁に接続された少なくとも1つの側壁を含み、前記底壁のそれぞれは前記各挿入部と前記容器の下位部との間の流体連通が可能になるように構成され、前記少なくとも1つの挿入部のそれぞれは、前記底壁の上部に足場をさらに備えるデバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10764008P | 2008-10-22 | 2008-10-22 | |
US61/107,640 | 2008-10-22 | ||
PCT/US2009/061727 WO2010048441A2 (en) | 2008-10-22 | 2009-10-22 | Culture systems |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012506258A JP2012506258A (ja) | 2012-03-15 |
JP2012506258A5 JP2012506258A5 (ja) | 2012-12-13 |
JP5669741B2 true JP5669741B2 (ja) | 2015-02-12 |
Family
ID=42119988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011533349A Expired - Fee Related JP5669741B2 (ja) | 2008-10-22 | 2009-10-22 | 培養システム |
Country Status (4)
Country | Link |
---|---|
US (3) | US20110294215A1 (ja) |
EP (1) | EP2350259A4 (ja) |
JP (1) | JP5669741B2 (ja) |
WO (1) | WO2010048441A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017146124A1 (ja) | 2016-02-22 | 2017-08-31 | 国立大学法人大阪大学 | 立体的細胞組織の製造方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2404672A1 (en) * | 2010-07-06 | 2012-01-11 | Universiteit Twente | High troughput multiwell system for culturing 3D tissue constructs in-vitro or in-vivo, method for producing said multiwell system and methods for preparing 3D tissue constructs from cells using said multiwell system |
KR101523425B1 (ko) * | 2013-06-10 | 2015-05-27 | 주승연 | 3차원 세포배양 키트 및 이를 이용한 3차원 세포배양 방법 |
WO2015124732A1 (en) * | 2014-02-21 | 2015-08-27 | Stichting Katholieke Universiteit | Blends of oligo(alkylene glycol) functionalized polyisocyanopeptides and fibrin for culturing cells |
JP6329836B2 (ja) * | 2014-07-24 | 2018-05-23 | 国立大学法人三重大学 | イメージング用小魚管理装置及びそれに用いられる小魚用イメージングプレート |
JP6583830B2 (ja) * | 2014-10-29 | 2019-10-02 | 国立大学法人山口大学 | 末梢血単核球又は末梢血単核球より分泌される因子を伴う線維芽細胞を含む細胞シート |
GB2553074B (en) * | 2016-02-05 | 2020-11-18 | Revivocell Ltd | A cell culture device |
JP2024516004A (ja) * | 2021-05-02 | 2024-04-11 | エンリッチ バイオシステムズ インコーポレイテッド | 粒子分離および分析のための破壊可能なマイクロウェルアレイ |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3751519T2 (de) * | 1986-04-18 | 1996-03-28 | Advanced Tissue Sciences Inc | Stromales Gewebe. |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
IL95429A (en) * | 1989-09-15 | 1997-09-30 | Organogenesis | Living tissue equivalents comprising hydrated collagen lattice and a collagen gel and their production |
GB9826701D0 (en) * | 1998-12-05 | 1999-01-27 | Univ Newcastle | Microcellular polymers as cell growth media and novel polymers |
US6197061B1 (en) * | 1999-03-01 | 2001-03-06 | Koichi Masuda | In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage |
WO2000055300A1 (en) * | 1999-03-18 | 2000-09-21 | Korea Advanced Institute Of Science And Technology | Method for preparing porous, biodegradable and biocompatible, polymeric scaffolds for tissue engineering |
US7759113B2 (en) * | 1999-04-30 | 2010-07-20 | The General Hospital Corporation | Fabrication of tissue lamina using microfabricated two-dimensional molds |
US7338773B2 (en) * | 2000-04-14 | 2008-03-04 | Millipore Corporation | Multiplexed assays of cell migration |
WO2003036265A2 (en) * | 2001-10-26 | 2003-05-01 | Virtual Arrays, Inc. | Assay systems with adjustable fluid communication |
US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
US7429492B2 (en) * | 2002-09-09 | 2008-09-30 | Sru Biosystems, Inc. | Multiwell plates with integrated biosensors and membranes |
DE20215659U1 (de) * | 2002-10-11 | 2004-02-19 | Alvito Biotechnologie Gmbh | Reagenzienkit zur Kultivierung von Zellen |
US20040091397A1 (en) * | 2002-11-07 | 2004-05-13 | Corning Incorporated | Multiwell insert device that enables label free detection of cells and other objects |
US8214256B2 (en) * | 2003-09-15 | 2012-07-03 | Time Warner Cable Inc. | System and method for advertisement delivery within a video time shifting architecture |
US7785883B2 (en) * | 2004-04-28 | 2010-08-31 | Vax Design Corp. | Automatable artificial immune system (AIS) |
EP1815244A4 (en) * | 2004-11-11 | 2009-07-22 | Agency Science Tech & Res | CELL CULTURE DEVICE |
FR2881434B1 (fr) * | 2005-02-02 | 2007-05-11 | Coletica Sa | Dispositif de support de culture de cellules |
US20070003595A1 (en) * | 2005-04-19 | 2007-01-04 | Shaopeng Wang | Three dimensional micro-environments and methods of making and using same |
US8663686B2 (en) * | 2005-05-09 | 2014-03-04 | University Of Washington | Biodegradable chitosan-PEG compositions and methods of use |
DK1893738T3 (en) * | 2005-06-10 | 2019-01-28 | Nunc As | CULTURAL ACTION CARRIER, CULTURE ACTION AND CULTURAL ACTION SYSTEM |
US8603806B2 (en) * | 2005-11-02 | 2013-12-10 | The Ohio State Universtiy Research Foundation | Materials and methods for cell-based assays |
WO2007070850A2 (en) * | 2005-12-14 | 2007-06-21 | Organogenesis, Inc. | Skin care compositions and treatments |
CN201193228Y (zh) * | 2007-02-13 | 2009-02-11 | 刘青 | 三维细胞培养插入件、其制造设备及成套用具 |
-
2009
- 2009-10-22 JP JP2011533349A patent/JP5669741B2/ja not_active Expired - Fee Related
- 2009-10-22 US US13/125,798 patent/US20110294215A1/en not_active Abandoned
- 2009-10-22 EP EP09822731.7A patent/EP2350259A4/en not_active Withdrawn
- 2009-10-22 WO PCT/US2009/061727 patent/WO2010048441A2/en active Application Filing
-
2013
- 2013-05-30 US US13/905,487 patent/US20130260465A1/en not_active Abandoned
- 2013-05-30 US US13/905,510 patent/US20130260451A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017146124A1 (ja) | 2016-02-22 | 2017-08-31 | 国立大学法人大阪大学 | 立体的細胞組織の製造方法 |
EP4349972A2 (en) | 2016-02-22 | 2024-04-10 | Osaka University | Method for producing three-dimensional cell tissue |
Also Published As
Publication number | Publication date |
---|---|
US20110294215A1 (en) | 2011-12-01 |
JP2012506258A (ja) | 2012-03-15 |
WO2010048441A2 (en) | 2010-04-29 |
US20130260451A1 (en) | 2013-10-03 |
WO2010048441A3 (en) | 2010-08-19 |
US20130260465A1 (en) | 2013-10-03 |
EP2350259A4 (en) | 2013-12-18 |
EP2350259A2 (en) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5669741B2 (ja) | 培養システム | |
JP4671365B2 (ja) | 高密度培養組織の製造方法及び高密度培養組織 | |
Malda et al. | Expansion of bovine chondrocytes on microcarriers enhances redifferentiation | |
JP3452366B2 (ja) | 新規人工組織、その製法およびその使用 | |
EP1835949B1 (en) | Tissue engineering devices for the repair and regeneration of tissue | |
CA2031532C (en) | Method for implanting large volumes of cells on polymeric matrices | |
US20110207175A1 (en) | Multi-culture bioreactor system | |
US20230048690A1 (en) | Scaffold with hierarchical structure, preparation method therefor and application thereof | |
US20110281351A1 (en) | Process for producing laminated high-density cultured artificial tissue, and laminated high-density cultured artificial tissue | |
US20080009064A1 (en) | Temperature-Responsive Microcarrier | |
US20100297233A1 (en) | Oscillating cell culture bioreactor | |
JP6434014B2 (ja) | 球状軟骨細胞治療剤の製造方法 | |
Vunjak-Novakovic et al. | Cell seeding of polymer scaffolds | |
WO2005014774A1 (ja) | 動物細胞の培養担体と、該培養担体を用いた動物細胞の培養方法および移植方法 | |
JP2003135056A (ja) | 移植用組織等価物の製造方法及びその製造用器具 | |
Ellis et al. | Bioreactor systems for tissue engineering: a four-dimensional challenge | |
CN111304168B (zh) | 三维生物打印的体内肿瘤模型及其构建方法 | |
Cohen et al. | Tissue engineering using human embryonic stem cells | |
Cao et al. | Three-dimensional culture of human mesenchymal stem cells in a polyethylene terephthalate matrix | |
Chen et al. | High-density culture of hepatocytes in a packed-bed bioreactor using a fibrous scaffold from plant | |
CN119301238A (zh) | 用于免疫细胞大规模扩增和激活的系统和方法 | |
JP4102557B2 (ja) | 人工組織用材料 | |
Ichinohe et al. | Proliferation, osteogenic differentiation, and distribution of rat bone marrow stromal cells in nonwoven fabrics by different culture methods | |
Zoldan et al. | Engineering three‐dimensional tissue structures using stem cells | |
Volkova et al. | Three-dimensional matrixes of natural and synthetic origin for cell biotechnology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121022 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121022 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140124 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140324 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141023 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5669741 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |